Notably, this finding aligns with an earlier result from Goel et al., which suggests that HPN should be considered a novel immunohistochemical marker for the histopathological diagnosis of PCa based on immunostaining intensity in normal prostate, low-scoring, and high-scoring PCa (102). The gene discussed is HPN; the disease is posterior cortical atrophy.